06.05.2026

Large International Study Finds No Link Between Semaglutide and Wet AMD Risk

Key Takeaways A study of 227,971 adults with type 2 diabetes found no evidence that semaglutide increases or decreases the risk of wet AMD Researchers compared semaglutide users with patients taking other GLP-1 receptor agonists and several non-GLP-1 diabetes medications, finding no statistically significant differences in AMD risk A large international study has found no evidence that semaglutide, the blockbuster diabetes and weight-loss medication, increases the risk of developing wet age-related macular degeneration (AMD).1 The research, published in Ophthalmology, examined health records from more than 227,000 adults with type 2 diabetes who were prescribed semaglutide. Investigators found that patients taking the drug were no more likely to develop wet AMD than patients using several other commonly prescribed diabetes medications.